Pharmac funds new HIV drug in New Zealand - Dolutegravir (Tivicay) | Body Positive News

Pharmac funds new HIV drug in New Zealand - Dolutegravir (Tivicay)

Dolutegravir (Tivicay)
Body Positive is thankful to Pharmac for adding Dolutegravir (Tivicay) to its list of Anti-Retroviral for the treatment of HIV effective November 1st 2016. Dolutegravir is a relatively new drug which was approved by Medsafe in 2014. It is in the class of Integrase Strand Transfer Inhibitors (INSTI) which make up four of the five recommended regimens for the initial treatment of HIV according to US Treatment Guidelines. Dolutegravir plus Truvada and Dolutegravir plus Kivexa are two of the recommended regimens and are taken once daily.

We recommend that people talk with their specialist about this new treatment option and consider whether this would be a good choice for them.